M. J. Lechuga Frean

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

S. Loi, H. Rugo, H. Iwata, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.

A. Ravaud, R. Figlin, A. Pantuck, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.